Media not available due to technical recording problems. EVRS is very sorry for the inconvenience.



Triamcinolone acetonide is a corticosteroid used in the treatment of macular edema of different etiologies. To the best of our knowledge, the duration of effect of this therapy has not been described in previously vitrectomized eyes.


Retrospective, descriptive, non-comparative study including eyes that underwent 23G pars plana vitrectomy and were subsequently treated with an intravitreal injection of triamcinolone for macular edema. We studied Best Corrected Visual Acuity, Intraocular Pressure and Central Macular Thickness (Cirrus TM HD-OCT Zeiss Meditec ®) before and after therapy, as well as the duration of the effect.

Effectiveness / Safety:

Eleven pseudophakic eyes of 9 patients were included. Macular edema was related to diabetic retinopathy (n=9 eyes), and followed vitrectomy for retinal detachment (n=1) and ocular trauma (n= 1). There was an increase of 3.30mmHg in mean intraocular pressure (p=0.0041). Central Macular Thickness (CMT) decreased from 489±145 to 229±171 approximately 18 days after the injection. CMT lowering effect of triamcinolone in vitrectomized eyes lasted a mean (±SD) of 11.62±3.46 weeks. Triamcinolone should be considered in the treatment of patients with persistent macular even after pars plana vitrectomy.